Clinical trials
Hepatic Fibrosis clinical trials
Below are recruiting hepatic fibrosis clinical trials, each written for real people, not researchers. We’re tracking 26 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06845345Enrolling by invitationPhase 4
Can a special diet or pills help liver health?
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
RotterdamAges 18–75 - NCT06779058Recruiting
Liver stiffness testing for hepatitis B patients
This trial uses MR elastography (a special MRI) to measure liver stiffness and check for fibrosis (scarring) without a needle biopsy. It may help guide treatment for chronic hepatitis B.
Shenyang, LiaoningAges 18–80 - NCT06601829Recruiting
Liver and kidney disease study in children
This study looks at children with congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. It aims to learn more about these conditions and how they affect children.
SohagAges Any age - NCT07201649Recruiting
Liver disease and artery calcification study
This study looks at how liver function and scarring affect calcium buildup in arteries. It may help people waiting for a liver transplant understand these changes.
Nice, Alpes-maritimesAges 18 years+ - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+ - NCT06599918RecruitingPhase 2
Nicotinamide for liver scarring in fatty liver disease
This study tests whether nicotinamide (a form of vitamin B3) can help reduce liver scarring in people with nonalcoholic fatty liver disease. You may qualify if you have moderate to severe liver scarring and are between 18 and 85 years old.
BarcelonaAges 18–85 - NCT02417740Recruiting
Study of the natural course of noncirrhotic portal hypertension
This study follows people with noncirrhotic portal hypertension (NCPH) or people at risk for it to better understand how the condition progresses over time. It does not sound like a medication trial—more like careful monitoring to learn what happens in different people.
Bethesda, MarylandAges 12–100 - NCT06619106Recruiting
Screening tool for minimal hepatic encephalopathy
This study tests a new cognitive tool to quickly and reliably detect minimal hepatic encephalopathy, a subtle brain change that can occur in people with liver disease. If you have a liver condition like fibrosis or cirrhosis and are already scheduled for a full evaluation (neuropsychological tests, MRI, EEG, and blood ammonia), this tool could help simplify future screening.
ParisAges 18–70 - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT06561529Recruiting
Stomach bypass stent for liver scarring in obese patients
This study tests a stomach bypass stent to treat liver scarring caused by fatty liver disease in people with obesity. If you have obesity and a confirmed liver condition called NASH with moderate scarring, this stent might help you achieve weight loss and improve your liver health.
Riga, RigaAges 18–65 - NCT06119997Recruiting
Liver fibrosis screening using simple blood tests in primary care
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
GrenobleAges 18–70 - NCT03308916Recruiting
Screening for liver scarring risk using noninvasive tests
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
OdenseAges 30–75 - NCT06755632Recruiting
Hepatic fibrosis or cirrhosis screening trial
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
BobignyAges 18 years+ - NCT05385237Recruiting
4D MRI scan to spot liver scarring
This study tests whether a special MRI scan (called 4D-MRI) can identify liver scarring or damage. It may help doctors measure liver fibrosis and inflammation without relying only on invasive tests.
Liestal, Basel-LandschaftAges 18 years+ - NCT05911620Recruiting
MRI test to measure liver scar severity in Cushing’s
This study uses a special MRI scan to measure how severe liver scarring is. It focuses on people with Cushing’s syndrome or suspected Cushing’s, or those with metabolic syndrome, to see how well the scan helps diagnose and assess severity.
NancyAges 18 years+ - NCT01401998Recruiting
Study collecting information from people with ARPKD
This study looks at medical records, imaging, and genetic testing for people with autosomal recessive polycystic kidney disease (ARPKD). It may help researchers better understand the condition and how it affects the liver and kidneys.
Washington D.C., District of ColumbiaAges Up to 18 years - NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+ - NCT05490888RecruitingPhase 1
Dose study of PHIN-214 for mild to moderate cirrhosis
This Phase 1 study tests how the medicine PHIN-214 behaves in the body and what dose is tolerable in people with Child-Pugh A or B liver cirrhosis. It may help doctors plan safer dosing for future studies.
Chandler, ArizonaAges 18–75 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT07128108Recruiting
Testing a new ultrasound for liver fat and scarring
This study tests a new ultrasound technique called Visual Transient Elastography (ViTE) to measure fat and scarring in the liver. If you recently had a liver biopsy, this noninvasive test could help check your liver health without another needle procedure.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06248580Recruiting
Finding HDV in Turkey Study
This trial is looking for adults in Turkey who have had a hepatitis B infection (HBsAg positive) for at least 6 months. The goal is to see if they also have a hepatitis D virus (HDV) infection. This may help doctors better understand and treat these infections.
AnkaraAges 18 years+ - NCT07202910Recruiting
Validating liver imaging in children
This study tests if non-invasive imaging (like ultrasound) can replace liver biopsies in children with liver disease. It may help avoid the need for a needle biopsy in the future.
Gothenburg, Västra Götaland CountyAges Up to 25 years
Hear when a new Hepatic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatic fibrosis?
- Yes. Clin2 currently lists 26 recruiting hepatic fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatic fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatic fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.